Maja de Jonge
Overview
Explore the profile of Maja de Jonge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1091
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
de Jonge M, de Weger V, Dickson M, Langenberg M, Cesne A, Wagner A, et al.
Eur J Cancer
. 2017 Mar;
76:144-151.
PMID: 28324749
Purpose: In tumours with wild-type TP53, the tumour-suppressive function of p53 is frequently inhibited by HDM2. This phase I, dose-escalating study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics and...
12.
de Leng W, Gadellaa-Van Hooijdonk C, Barendregt-Smouter F, Koudijs M, Nijman I, Hinrichs J, et al.
PLoS One
. 2016 Feb;
11(2):e0149405.
PMID: 26919633
Background: Targeted Next Generation Sequencing (NGS) offers a way to implement testing of multiple genetic aberrations in diagnostic pathology practice, which is necessary for personalized cancer treatment. However, no standards...
13.
Verweij J, de Jonge M, Eskens F, Sleijfer S
Mol Oncol
. 2012 Mar;
6(2):196-203.
PMID: 22386481
With the event of new Molecular targets, clinical trial design requirements to perform these trials are changing. This paper discusses some of the considerations that need to be taken into...
14.
Bendell J, Rodon J, Burris H, de Jonge M, Verweij J, Birle D, et al.
J Clin Oncol
. 2011 Dec;
30(3):282-90.
PMID: 22162589
Purpose: This phase I dose-escalation study investigated the maximum-tolerated dose (MTD), safety, preliminary activity, pharmacokinetics (PK), and pharmacodynamics of BKM120, a potent and highly specific oral pan-Class I PI3K inhibitor....
15.
Hamberg P, Woo M, Chen L, Verweij J, Porro M, Zhao L, et al.
Cancer Chemother Pharmacol
. 2011 Jun;
68(3):805-13.
PMID: 21706316
Purpose: Panobinostat is partly metabolized by CYP3A4 in vitro. This study evaluated the effect of a potent CYP3A inhibitor, ketoconazole, on the pharmacokinetics and safety of panobinostat. Methods: Patients received...
16.
Guttman-Yassky E, Mita A, de Jonge M, Matthews L, McCarthy S, Iwata K, et al.
Eur J Cancer
. 2010 Jul;
46(11):2010-9.
PMID: 20621734
Introduction: EGFR inhibitors (EGFRIs) have been shown to be clinically effective in various cancers. Unique skin toxicity is commonly observed with EGFRIs and a correlation between the clinical benefit of...
17.
Verweij J, Eskens F, de Jonge M
J Clin Oncol
. 2008 Apr;
26(12):1915-6.
PMID: 18421042
No abstract available.
18.
19.
20.
de Jonge M, Verweij J
J Clin Oncol
. 2005 Nov;
23(36):9048-50.
PMID: 16301592
No abstract available.